Skip to main content

Table 1 Causes of Death in patients enrolled in the study

From: Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

 

Number of patients

Duration of treatment

< 1 year

>1 year

Treatment-related mortality

-

-

Hepatocarcinoma

-

1

Hepato-renal syndrome

-

1

Esophagic varices bleeding

-

1

Heart attack

-

1

Percent of enrolled patients death

0%

9%

  1. Note: 2 patients were excluded from the study due to lack of monitoring.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us